MyMD Pharmaceuticals Inc. (NASDAQ: MYMD)
$1.91
+0.0100 ( +0.53% ) 2.3K
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
Market Data
Open
$1.91
Previous close
$1.90
Volume
2.3K
Market cap
$4.50M
Day range
$1.86 - $1.91
52 week range
$1.75 - $63.90
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
def | Proxies and info statements | 4 | Jul 01, 2024 |
3 | Insider transactions | 1 | Jun 28, 2024 |
8-k | 8K-related | 14 | Jun 24, 2024 |
8-k/a | 8K-related | 13 | Jun 20, 2024 |
pre | Proxies and info statements | 4 | Jun 20, 2024 |
8-k | 8K-related | 17 | Jun 17, 2024 |
3 | Insider transactions | 1 | May 30, 2024 |
8-k | 8K-related | 15 | May 23, 2024 |
8-k | 8K-related | 26 | May 21, 2024 |
3 | Insider transactions | 1 | May 16, 2024 |